RESUMO
Iproplatin (CHIP) was administered to 35 previously treated women with metastatic adenocarcinoma of the breast. The drug was given at a dose of 45 mg/m2 intravenously for 5 consecutive days and was repeated every 28 days. In this trial, there was one partial response and two patients with stable disease out of 29 evaluable patients. The median duration of response in patients with either a partial response or stable disease was 4.8 months. Myelosuppression was the major toxicity, 11 patients had severe thrombocytopenia and 3 severe neutropenia. Mild renal insufficiency, anemia, and nausea and vomiting were also noted. Iproplatin has limited activity in heavily pretreated women with advanced breast carcinoma; further studies in patients less heavily treated may show an improved response rate.
Assuntos
Adenocarcinoma/tratamento farmacológico , Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Compostos Organoplatínicos/uso terapêutico , Adenocarcinoma/secundário , Antineoplásicos/efeitos adversos , Avaliação de Medicamentos , Feminino , Humanos , Pessoa de Meia-Idade , Metástase Neoplásica , Compostos Organoplatínicos/efeitos adversos , Indução de Remissão , Trombocitopenia/induzido quimicamenteRESUMO
Procainamide hydrochloride-induced thrombocytopenia has infrequently been reported in the past. We report six cases of thrombocytopenia following the administration of the sustained-release form of procainamide. Three of these cases had platelet counts of less than 15,000/microL. The mean time to onset of thrombocytopenia from drug administration was 40 days (range, nine to 71 days). The mean time until normalization of the platelet counts after the drug therapy was stopped was 7.8 +/- 3.1 days (range, four to nine days). Oral prednisone therapy had little apparent benefit. The thrombocytopenia was not part of a systemic lupus erythematosus syndrome. We believe that thrombocytopenia is an important side effect of sustained-release procainamide therapy.
Assuntos
Procainamida/efeitos adversos , Trombocitopenia/induzido quimicamente , Acecainida/sangue , Acetilação , Adulto , Idoso , Anticorpos Antinucleares/análise , Preparações de Ação Retardada , Humanos , Lúpus Eritematoso Sistêmico/induzido quimicamente , Pessoa de Meia-Idade , Fenótipo , Procainamida/administração & dosagem , Procainamida/sangue , Trombocitopenia/imunologia , Fatores de TempoRESUMO
To our knowledge, thoracic empyema caused by Haemophilus parainfluenzae has not been described previously. A case occurred in the setting of alcoholism and chronic obstructive pulmonary disease. We note the similarity to pulmonary infections with H influenzae and discuss the implications for antibiotic therapy.
